Navigation Links
Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting

-------------------------- -------------- Sunday 8am-12pm Synergistic inhibition of tumor Xiongwen Zhang April 15 growth by combined treatment with MD, PhD the pan Bcl-2 inhibitor AT-101 Ascenta and docetaxel in human cancer Therapeutics. xenograft models ---------------------------------- -------------- A novel small molecular inhibitor Jason Canner targets the MDM2-p53 interaction DO, Columbus significantly reducing cell Children's viability in both embryonal and Hospital alveolar rhabdomyosarcoma cells with wild-type p53 --------- ---------------------------------- -------------- 1pm-5pm AT-101-induced apoptosis in VCaP Robert Loberg androgen-sensitive cells is PhD inhibited by the presence of DHT U. Michigan ---------------------------------- -------------- Synergistic effect of AT-101, an Xiongwen orally active pan-Bcl-2 family Zhang, MD, protein inhibitor in combination PhD with dual-Raf/MEK and VEGFR Ascenta kinase inhibitor sorafenib Therapeutics (Nexavar(R)) --------- --------- ---------------------------------- -------------- Tuesday 3:30pm Preclinical characterization of Dajun Yang, April 17 MI-219, a novel potent oral small MD, PhD molecule inhibitor of the MDM2- Ascenta p53 interaction Therapeutics --------- ---------------------------------- -------------- 1pm-5pm Synergistic anti-tumor effect with Nathalie combinat
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/28/2015)... ALTO, Calif. , July 28, 2015 ... Holding Corp., the parent company of CPI International, Inc. ... third quarter ended July 3, 2015 with the Securities ... regarding its results for the quarter.  At 11 a.m. ... a telephonic conference call in conjunction with this release ...
(Date:7/28/2015)... PARK, Calif. , July 28, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based ... announced the publication of the SENZA-RCT results in ... official Journal of the American Society of Anesthesiologists. ... a ground-breaking study that was the first to ...
(Date:7/28/2015)... 28, 2015  SeraCare Life Sciences, a leading ... today at the American Association of Clinical Chemistry ... agreement with the University of California, San Francisco ... Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast ... "patient-like" reference materials for Non-Invasive Prenatal Testing (NIPT) ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3
... Major Lupin Limited announced today that its U.S. subsidiary, ... Award by the Healthcare Distribution Management Association (HDMA) for ... with sales of up to $100 million in the ... winners are selected by HDMA Distributor members to recognize ...
... Laboratories, a leading provider of medication monitoring services to ... hiring of Martin Price as General Counsel and Janna ... Officer. As Millennium Laboratories General Counsel, Mr. ... Howard Appel , Millennium Laboratories, President, said, "We ...
Cached Medicine Technology:HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 2HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 3Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 2Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 3
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a talk on ... noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center ... is board-certified in colorectal surgery and has more than 35 years of experience in ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
(Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... targeted biologics and biologic-device combination products for the treatment of bone disorders and ... U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
Breaking Medicine News(10 mins):Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... on an enzyme that is critical to the process ... target of antibacterial and anticancer drugs. Researchers with the ... Lab) and the University of California (UC) at Berkeley ... DNA-bound Type II topoisomerase (topo II) that is responsible ...
... for Dealing With Elderly Holiday Blues Offered by One of the ... ... of the country,s senior,healthcare experts from the world-renowned Los Angeles Jewish ... group,particularly vulnerable to the blues at this time of year -- ...
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... children , , THURSDAY, Dec. 20 (HealthDay News) -- Holiday toys ... are threatening to cause more worry than joy. , Millions ... months by toy companies, many because they were decorated with ... Barbie, and Thomas the Tank Engine, among others. , The ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
Cached Medicine News:Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:First look at an enzyme target for antibacterial and cancer drugs 2Health News:First look at an enzyme target for antibacterial and cancer drugs 3Health News:First look at an enzyme target for antibacterial and cancer drugs 4Health News:It's Not Just About the Children 2Health News:It's Not Just About the Children 3Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Make Safe Toys Your Holiday Priority 2Health News:Make Safe Toys Your Holiday Priority 3Health News:Gloomy forecast for Nobel Direct after 3 years 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: